This month we’ll revisit two issues covered previously: attempts to promote compulsory licensing as a way for lowering the cost of Medicare drugs and increasing the return on investment from federally-supported R&D.
Last month we discussed Rep. Lloyd Doggett’s (D-TX) bill allowing the government to issue compulsory licenses if a company won’t sell a drug to Medicare for the price the feds wants to pay. In a recent “Dear Democratic Colleague” message seeking co-sponsors for his effort Rep. Doggett’s office says:
